Janux Doses First Patient in Phase 1 Trial of Prostate Cancer Therapy JANX013 — Janux Therapeutics, Inc.

Event summary

First patient dosed in Phase 1 trial of JANX013, a PSMA-targeted CD28 co-stimulatory bispecific, for metastatic castration-resistant prostate cancer (mCRPC).
JANX013 is being evaluated in combination with JANX007 to enhance anti-tumor immune responses.
Phase 1 trial (NCT07813637) is an open-label, multicenter study assessing safety, tolerability, and preliminary efficacy.
Prostate cancer is the most commonly diagnosed cancer in men, excluding skin cancers.

The big picture

Janux Therapeutics is advancing its tumor-activated immunotherapy platform with the initiation of the JANX013 Phase 1 trial, targeting a critical unmet need in prostate cancer treatment. The company's focus on tumor-restricted CD28 co-stimulation aims to improve the durability of immune responses, aligning with broader industry trends toward precision immunotherapies. The success of this trial could position Janux as a key player in the evolving landscape of oncology treatments.

What we're watching

Clinical Efficacy: How the combination of JANX013 and JANX007 will affect the durability of anti-tumor immune responses in mCRPC patients.
Regulatory Pathway: The pace at which Janux can advance JANX013 through clinical trials and secure regulatory approvals.
Pipeline Expansion: Whether Janux can successfully integrate JANX013 into its broader prostate cancer portfolio and explore additional combinations.